Understanding immune responses in glioblastoma to enhance treatment outcomes
Official title: Dissecting Orchestrated Immune Responses to Glioblastoma within the Native Tissue Microenvironment to Improve Treatment Outcomes
Funded at Beth Israel Deaconess Medical Center · NIH-11162569 · Data updated 2026-11-12
This study is looking at how the immune system and glioblastoma cells work together in the brain, using samples from patients and mice to see how the tumor's location affects how it responds to treatments like radiation and chemotherapy, with the hope of finding better ways to help patients based on their unique tumor features.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | May 15, 2025 |
| Project end | February 28, 2030 |
| Funding year | 2025 |
| Award (this year) | $687,279 |
| NIH project number | 1R01NS139479-01A1 |
| Project ID | NIH-11162569 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with glioblastoma who are undergoing standard treatment.
✕Less likely to help
Patients with other types of brain tumors or those who are not receiving standard glioblastoma treatments may not benefit from this research.
What this research studies
This research investigates how the immune system interacts with glioblastoma cells within the tumor microenvironment. By analyzing both human patient samples and mouse models, the study aims to uncover how the location of tumor cells affects their behavior and response to standard treatments like radiation and chemotherapy. The researchers will utilize advanced techniques such as single-cell RNA sequencing to gain insights into the cellular diversity and dynamics of glioblastoma, which could lead to improved therapeutic strategies. Patients may benefit from a better understanding of how their specific tumor characteristics influence treatment effectiveness.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment strategies for glioblastoma patients, potentially improving survival rates.
How similar studies have gone: Previous research has shown promise in understanding tumor microenvironments and immune interactions, suggesting that this approach could yield significant insights.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Charest, Alain — Beth Israel Deaconess Medical Center
- Study coordinator: Charest, Alain
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.